Follistatin 344 as a myostatin inhibitor blocks the TGF-beta pathway that caps muscle growth. Here is the mechanism, the difference from Follistatin 315, and what skeletal muscle research models have documented.
Follistatin 344 as a myostatin inhibitor targets the fundamental brake on skeletal muscle growth: the TGF-beta signaling pathway. Myostatin (GDF-8) signals muscle cells to stop growing, and Follistatin 344 neutralizes it directly in circulation.
Myostatin is a member of the TGF-β superfamily that suppresses protein synthesis and inhibits satellite cell activation. Myostatin inhibition research in the Journal of Clinical Investigation demonstrated that adult myostatin removal produces significant hypertrophy.
In research models, Follistatin administration has documented muscle mass increases far exceeding normal physiological ceilings. By sequestering myostatin in the extracellular space, it prevents SMAD2/3 signaling that would otherwise limit hypertrophy.
Follistatin-344 contains a heparin-binding domain that anchors it to local tissue, making it ideal for studying site-specific muscle growth. In contrast, Follistatin-315 circulates systemically. Beyond Health Lab supplies Follistatin 344 1mg at ≥99% verified purity.
Join 10,000+ researchers. Get your discount code, early access to new compounds, and protocol insights.
No spam, ever. Unsubscribe anytime.
Check your inbox for your discount code.
Here's a preview:
Valid on all products · Single use
